Details of the Drug

General Information of Drug (ID: DM3JCVS)

Drug Name

Terazosin

Synonyms

Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Terazosabb; Terazosina; Terazosine; Terazosinum; Vasomet; Trazosin HCl; A 45975; Abbott 45975; A-45975; Hytrin (TN); Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina [INN-Spanish]; Terazosine [INN-French]; Terazosinum [INN-Latin]; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine

Indication

Disease Entry	ICD 11	Status	REF
Benign prostatic hyperplasia	GA90	Approved	[1], [2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

387.4

Topological Polar Surface Area (xlogp)

1.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The absorption of drug is 90% [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: 90% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The renal clearance of drug is 10 mL/min [3]
Elimination: Approximately 10% of the oral dose is excreted unchanged in the urine and approximately 20% is excreted in the feces [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 12 hours [3]
Metabolism: The drug is metabolized via the hepatic [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.85948 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.08% [7]
Vd: The volume of distribution (Vd) of drug is 25-30 L [3]
Water Solubility: The ability of drug to dissolve in water is measured as 24.2 mg/mL [4]

Chemical Identifiers

Formula: C19H25N5O4
IUPAC Name: [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
Canonical SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
InChI: InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
InChIKey: VCKUSRYTPJJLNI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5401
ChEBI ID: CHEBI:9445
CAS Number: 63590-64-7
DrugBank ID: DB01162
TTD ID: D0P9RF
VARIDT ID: DR00869
ACDINA ID: D00662

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Antagonist	[8], [9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Terazosin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Terazosin and Silodosin.	Prostate hyperplasia [GA90]	[19]
-----------

Coadministration of a Drug Treating the Disease Different from Terazosin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Terazosin and Cariprazine.	Bipolar disorder [6A60]	[20]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Terazosin and Isocarboxazid.	Depression [6A70-6A7Z]	[21]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Terazosin and OPC-34712.	Depression [6A70-6A7Z]	[20]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Terazosin and Nadolol.	Essential hypertension [BA00]	[22]
Metipranolol	DMJMVKI	Moderate	Additive hypotensive effects by the combination of Terazosin and Metipranolol.	Glaucoma [9C61]	[22]
Levobetaxolol	DMSREPX	Moderate	Additive hypotensive effects by the combination of Terazosin and Levobetaxolol.	Glaucoma [9C61]	[22]
Levobunolol	DMTNFCQ	Moderate	Additive hypotensive effects by the combination of Terazosin and Levobunolol.	Glaucoma [9C61]	[22]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Terazosin and Procarbazine.	Hodgkin lymphoma [2B30]	[21]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Terazosin and Acebutolol.	Hypertension [BA00-BA04]	[22]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Terazosin and Captopril.	Hypertension [BA00-BA04]	[23]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Terazosin and Penbutolol.	Hypertension [BA00-BA04]	[22]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Terazosin and Nebivolol.	Hypertension [BA00-BA04]	[22]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Terazosin and ITI-007.	Insomnia [7A00-7A0Z]	[20]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Terazosin and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[24]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Terazosin and Lasmiditan.	Migraine [8A80]	[25]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Terazosin and Ozanimod.	Multiple sclerosis [8A40]	[21]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Terazosin and Rasagiline.	Parkinsonism [8A00]	[21]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Terazosin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[20]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Terazosin and Quetiapine.	Schizophrenia [6A20]	[20]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Terazosin and Aripiprazole.	Schizophrenia [6A20]	[20]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Terazosin and Iloperidone.	Schizophrenia [6A20]	[20]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Terazosin and Paliperidone.	Schizophrenia [6A20]	[20]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Terazosin and Molindone.	Schizophrenia [6A20]	[20]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Terazosin and Thiothixene.	Schizophrenia [6A20]	[20]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Terazosin and Amisulpride.	Schizophrenia [6A20]	[20]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Terazosin and Asenapine.	Schizophrenia [6A20]	[20]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Terazosin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[26]
-----------


⏷ Show the Full List of 27 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Aluminum chlorohydrex propylene glycol	E00594	71587575	Other agent
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone	E00626	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Terazosin 2 mg capsule	2 mg	Oral Capsule	Oral
Terazosin 10 mg capsule	10 mg	Oral Capsule	Oral
Terazosin 5 mg capsule	5 mg	Oral Capsule	Oral
Terazosin 1 mg capsule	1 mg	Oral Capsule	Oral
Terazosin Hydrochloride eq 10mg base capsule	eq 10mg base	Capsule	Oral
Terazosin Hydrochloride eq 2mg base capsule	eq 2mg base	Capsule	Oral
Terazosin Hydrochloride eq 1mg base tablet	eq 1mg base	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7302).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074823.
3	Pharmacokinetics of terazosin. Am J Med. 1986 May 23;80(5B):20-4.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
9	Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nat Med. 2000 Dec;6(12):1388-94.
10	The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
11	Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
12	Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
13	Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
14	Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
15	The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
16	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
17	Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
18	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
19	Product Information. Flomax (tamsulosin). Boehringer-Ingelheim, Ridgefield, CT.
20	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
21	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
22	Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
23	Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
24	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
25	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
26	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.